Your browser doesn't support javascript.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Emary, Katherine R W; Golubchik, Tanya; Aley, Parvinder K; Ariani, Cristina V; Angus, Brian; Bibi, Sagida; Blane, Beth; Bonsall, David; Cicconi, Paola; Charlton, Sue; Clutterbuck, Elizabeth A; Collins, Andrea M; Cox, Tony; Darton, Thomas C; Dold, Christina; Douglas, Alexander D; Duncan, Christopher J A; Ewer, Katie J; Flaxman, Amy L; Faust, Saul N; Ferreira, Daniela M; Feng, Shuo; Finn, Adam; Folegatti, Pedro M; Fuskova, Michelle; Galiza, Eva; Goodman, Anna L; Green, Catherine M; Green, Christopher A; Greenland, Melanie; Hallis, Bassam; Heath, Paul T; Hay, Jodie; Hill, Helen C; Jenkin, Daniel; Kerridge, Simon; Lazarus, Rajeka; Libri, Vincenzo; Lillie, Patrick J; Ludden, Catherine; Marchevsky, Natalie G; Minassian, Angela M; McGregor, Alastair C; Mujadidi, Yama F; Phillips, Daniel J; Plested, Emma; Pollock, Katrina M; Robinson, Hannah; Smith, Andrew; Song, Rinn.
  • Emary KRW; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Golubchik T; Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Aley PK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Ariani CV; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
  • Angus B; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Bibi S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Blane B; COVID-19 Genomics UK, Department of Medicine, University of Cambridge, Cambridge, UK.
  • Bonsall D; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Cicconi P; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Charlton S; National Infection Service, Public Health England, Salisbury, UK.
  • Clutterbuck EA; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Collins AM; Department of Clinical Sciences, Liverpool School of Tropical Medicine and Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
  • Cox T; UK Biocentre, Milton Keynes, UK.
  • Darton TC; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK; Department of Infection and Tropical Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Dold C; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Douglas AD; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Duncan CJA; Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; Translational and Clinical Research Institute, Immunity and Inflammation Theme, Newcastle University, Newcastle upon Tyne, UK.
  • Ewer KJ; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Flaxman AL; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Faust SN; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
  • Ferreira DM; Department of Clinical Sciences, Liverpool School of Tropical Medicine and Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
  • Feng S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Finn A; University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
  • Folegatti PM; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Fuskova M; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Galiza E; St George's Vaccine Institute, St George's, University of London, London, UK.
  • Goodman AL; Department of Infection, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, London, UK; MRC Clinical Trials Unit, University College London, London, UK.
  • Green CM; Clinical BioManufacturing Facility, University of Oxford, Oxford, UK.
  • Green CA; NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Greenland M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Hallis B; National Infection Service, Public Health England, Salisbury, UK.
  • Heath PT; St George's Vaccine Institute, St George's, University of London, London, UK.
  • Hay J; University of Glasgow, Glasgow, UK; Lighthouse Laboratory in Glasgow, Queen Elizabeth University Hospital, Glasgow, UK.
  • Hill HC; Department of Clinical Sciences, Liverpool School of Tropical Medicine and Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
  • Jenkin D; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Kerridge S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Lazarus R; Severn Pathology, North Bristol NHS Trust, Bristol, UK.
  • Libri V; NIHR UCLH Clinical Research Facility, London, UK; NIHR UCLH Biomedical Research Centre, London, UK.
  • Lillie PJ; Hull University Teaching Hospitals NHS Trust, Hull, UK.
  • Ludden C; COVID-19 Genomics UK, Department of Medicine, University of Cambridge, Cambridge, UK.
  • Marchevsky NG; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Minassian AM; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • McGregor AC; London Northwest University Healthcare, Harrow, UK.
  • Mujadidi YF; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Phillips DJ; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Plested E; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Pollock KM; NIHR Imperial Clinical Research Facility, London, UK; NIHR Imperial Biomedical Research Centre, London, UK.
  • Robinson H; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Smith A; College of Medical, Veterinary & Life Sciences, Glasgow Dental Hospital and School, University of Glasgow, Glasgow, UK.
  • Song R; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Lancet ; 397(10282): 1351-1362, 2021 04 10.
Article in English | MEDLINE | ID: covidwho-1157794
Semantic information from SemMedBD (by NLM)
1. 2019 novel coronavirus CAUSES Disease
Subject
2019 novel coronavirus
Predicate
CAUSES
Object
Disease
2. Adenoviridae vaccine PART_OF Disease Vectors
Subject
Adenoviridae vaccine
Predicate
PART_OF
Object
Disease Vectors
3. Microneutralization Assay MEASURES Antibody Formation
Subject
Microneutralization Assay
Predicate
MEASURES
Object
Antibody Formation
4. COVID-19 PROCESS_OF Participant
Subject
COVID-19
Predicate
PROCESS_OF
Object
Participant
5. Participant USES Swab
Subject
Participant
Predicate
USES
Object
Swab
6. B variant NOS PART_OF 2019 novel coronavirus
Subject
B variant NOS
Predicate
PART_OF
Object
2019 novel coronavirus
7. 2019 novel coronavirus CAUSES Disease
Subject
2019 novel coronavirus
Predicate
CAUSES
Object
Disease
8. Adenoviridae vaccine PART_OF Disease Vectors
Subject
Adenoviridae vaccine
Predicate
PART_OF
Object
Disease Vectors
9. Microneutralization Assay MEASURES Antibody Formation
Subject
Microneutralization Assay
Predicate
MEASURES
Object
Antibody Formation
10. COVID-19 PROCESS_OF Participant
Subject
COVID-19
Predicate
PROCESS_OF
Object
Participant
11. Participant USES Swab
Subject
Participant
Predicate
USES
Object
Swab
12. B variant NOS PART_OF 2019 novel coronavirus
Subject
B variant NOS
Predicate
PART_OF
Object
2019 novel coronavirus
ABSTRACT

BACKGROUND:

A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant.

METHODS:

Volunteers (aged ≥18 years) who were enrolled in phase 2/3 vaccine efficacy studies in the UK, and who were randomly assigned (11) to receive ChAdOx1 nCoV-19 or a meningococcal conjugate control (MenACWY) vaccine, provided upper airway swabs on a weekly basis and also if they developed symptoms of COVID-19 disease (a cough, a fever of 37·8°C or higher, shortness of breath, anosmia, or ageusia). Swabs were tested by nucleic acid amplification test (NAAT) for SARS-CoV-2 and positive samples were sequenced through the COVID-19 Genomics UK consortium. Neutralising antibody responses were measured using a live-virus microneutralisation assay against the B.1.1.7 lineage and a canonical non-B.1.1.7 lineage (Victoria). The efficacy analysis included symptomatic COVID-19 in seronegative participants with a NAAT positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to vaccine received. Vaccine efficacy was calculated as 1 - relative risk (ChAdOx1 nCoV-19 vs MenACWY groups) derived from a robust Poisson regression model. This study is continuing and is registered with ClinicalTrials.gov, NCT04400838, and ISRCTN, 15281137.

FINDINGS:

Participants in efficacy cohorts were recruited between May 31 and Nov 13, 2020, and received booster doses between Aug 3 and Dec 30, 2020. Of 8534 participants in the primary efficacy cohort, 6636 (78%) were aged 18-55 years and 5065 (59%) were female. Between Oct 1, 2020, and Jan 14, 2021, 520 participants developed SARS-CoV-2 infection. 1466 NAAT positive nose and throat swabs were collected from these participants during the trial. Of these, 401 swabs from 311 participants were successfully sequenced. Laboratory virus neutralisation activity by vaccine-induced antibodies was lower against the B.1.1.7 variant than against the Victoria lineage (geometric mean ratio 8·9, 95% CI 7·2-11·0). Clinical vaccine efficacy against symptomatic NAAT positive infection was 70·4% (95% CI 43·6-84·5) for B.1.1.7 and 81·5% (67·9-89·4) for non-B.1.1.7 lineages.

INTERPRETATION:

ChAdOx1 nCoV-19 showed reduced neutralisation activity against the B.1.1.7 variant compared with a non-B.1.1.7 variant in vitro, but the vaccine showed efficacy against the B.1.1.7 variant of SARS-CoV-2.

FUNDING:

UK Research and Innovation, National Institute for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midlands NIHR Clinical Research Network, and AstraZeneca.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Subject: Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Controlled clinical trial / Etiology study / Prognostic study Language: English Journal: Lancet Clinical aspect: Etiology Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Subject: Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Controlled clinical trial / Etiology study / Prognostic study Language: English Journal: Lancet Clinical aspect: Etiology Year: 2021
...